GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (FRA:2GH) » Definitions » Price-to-Owner-Earnings

Merus NV (FRA:2GH) Price-to-Owner-Earnings : (As of May. 24, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Merus NV Price-to-Owner-Earnings?

As of today (2025-05-24), Merus NV's share price is €42.60. Merus NV does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Merus NV's Price-to-Owner-Earnings or its related term are showing as below:


FRA:2GH's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.53
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-24), Merus NV's share price is €42.60. Merus NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-3.75. Therefore, Merus NV's PE Ratio (TTM) for today is At Loss.

As of today (2025-05-24), Merus NV's share price is €42.60. Merus NV's EPS without NRI for the trailing twelve months (TTM) ended in was €-3.80. Therefore, Merus NV's PE Ratio without NRI for today is At Loss.


Merus NV Price-to-Owner-Earnings Historical Data

The historical data trend for Merus NV's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Price-to-Owner-Earnings Chart

Merus NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merus NV Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Merus NV's Price-to-Owner-Earnings

For the Biotechnology subindustry, Merus NV's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Merus NV's Price-to-Owner-Earnings falls into.


;
;

Merus NV Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Merus NV's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=42.60/-2.76
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merus NV  (FRA:2GH) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Merus NV Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Merus NV's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV Business Description

Industry
Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV Headlines

No Headlines